Schedule 13G ownership disclosure

Candel Therapeutics Inc

Common stock, par value $0.0001 per share · CUSIP: 137404109

Event date: 2025-06-25

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ACORN BIOVENTURES, L.P.

    Shares: 1,083,818.00 · Class: 2.2%

  • ACORN BIOVENTURES 2, L.P.

    Shares: 1,496,699.00 · Class: 3.0%

  • ACORN CAPITAL ADVISORS GP, LLC

    Shares: 1,083,818.00 · Class: 2.2%

  • Acorn Capital Advisors GP2, LLC

    Shares: 1,496,699.00 · Class: 3.0%

  • Anders Hove

    Shares: 2,580,517.00 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001636587-25-000035
Form type
SCHEDULE 13G
Filer
ACORN BIOVENTURES, L.P.
CIK
CIK 1766853
Filed
Jun 30, 2025
Reporting period
Jun 25, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub